SNCA and Parkinson disease: Earlier work by Chung et al., 2017 suggests that monomeric non-pathological α-synuclein inhibits protein synthesis [101]; the findings of this study coupled with our own may suggest that part of the pathological transition in PD is that from monomeric non-pathologic α-synuclein, which decreases protein synthesis, to pathologic α-synuclein, which enhances protein synthesis.